Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (Q24625697)

13

Elizabeth M Brunt

0 references

Kris V. Kowdley

3

Kris V Kowdley

0 references

Joel E Lavine

8

Joel E Lavine

0 references

Mark Van Natta

11

Mark Van Natta

0 references

author name string

Arun J Sanyal

1

0 references

Naga Chalasani

2

0 references

Arthur McCullough

4

0 references

Anna Mae Diehl

5

0 references

Nathan M Bass

6

0 references

Brent A Neuschwander-Tetri

7

0 references

James Tonascia

9

0 references

Aynur Unalp

10

0 references

Jeanne Clark

12

0 references

Jay H Hoofnagle

15

0 references

Patricia R Robuck

The New England Journal of Medicine

16

0 references

language of work or name

English

0 references

publication date

6 May 2010

0 references

published in

0 references

volume

362

0 references

page(s)

1675-85

0 references

issue

18

0 references

cites work

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Long-term follow-up of patients with NAFLD and elevated liver enzymes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Mechanisms of non-alcoholic steatohepatitis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Diabetes drugs tied to fractures in women

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

Nonalcoholic steatohepatitis: an expanded clinical entity.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928471

The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis

28 November 2018

1 reference

12 December 2020

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

1 reference

12 December 2020

Identification of Alcohol Abuse Using Laboratory Tests and a History of Trauma

1 reference

12 December 2020

The AUDIT questionnaire: choosing a cut-off score. Alcohol Use Disorder Identification Test

1 reference

12 December 2020

Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA0907929

1 reference

688209

688209

1 reference

1 reference

1 reference